This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Haemonetics To Provide An Update On Key Growth Initiatives At J.P. Morgan Health Care Conference

Blood Management Solutions:   OrthoPAT Advance Device The next-generation OrthoPAT perioperative autotransfusion device, the OrthoPAT Advance which received a 510K approval in Q3 of fiscal 2013, has been designed with new features and capabilities that directly address ease-of-use and other features suggested by customers.  This new product offering is on track for limited market release to identified U.S. hospital customers in the first half of fiscal 2014.  

Blood Management Solutions:   Emerging Market Growth Investments The company is committed to increasing investment levels in emerging market growth initiatives, principally in China.  Such investments have led to an increase in Haemonetics' employment level in China and rapid acceptance of the company's thromboelastography ® ("TEG") diagnostic and cell salvage ("Cell Saver Elite") product offerings by key opinion leader surgeons and hospitals in key Chinese provinces.  New surgical applications for these products have expanded their served markets.

Planned Hemerus Medical, LLC Acquisition On September 17, 2012, the company indicated that the U.S. FDA had requested additional information from Hemerus.  Hemerus remains on track to provide the required information to the FDA later this month.

Mr. Concannon concluded: "We look forward to discussing these key business initiatives at this year's J.P. Morgan Healthcare Conference.  Together they represent exciting growth opportunities and we are confident in their progress.  They are the kinds of initiatives our customers expect from the global leader of blood management solutions as they seek ways to reduce costs and improve clinical outcomes."

As previously announced, the public may access Mr. Concannon's presentation live at http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=HAE and that webcast will be archived and available for approximately 90 days.

About Haemonetics Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers.  Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world.  Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.  To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

Cautionary / Safe Harbor Language This release contains forward-looking statements which involve risks and uncertainties, including the approval of new products by regulatory bodies, particularly the U.S. Food and Drug Administration, effects of disruption from the acquisition of the Pall Transfusion Medicine business making it more difficult to maintain relationships with employees, customers, vendors and other business partners, unexpected expenses incurred to integrate the Pall Transfusion Medicine business, the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate, technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, product quality, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of communicable diseases and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. 

Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict.  Actual results and experience could differ materially from the forward-looking statements. Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.

Stock quotes in this article: HAE 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs